Led · Series A · Jun 2026

Myota develops patented prebiotic fibre blends and positions its products for both consumer supplement and food-industry applications. The company emphasizes science-first development and has validated outcomes in clinical trials. Current commercial partnerships include a global deal with JOE & THE JUICE, supply agreements with a fast-growing coffee-alternative brand, and product development with major players in dairy, bakery and functional beverages. Distribution partnerships with Suannutra and Denava extend its reach across the UK, US, and EU. Myota’s D2C channel grew rapidly last year, tripling to surpass 60,000 customers. With the new funding, the company plans to scale B2B sales in Europe and the US and expand clinical research.

Participated · Series A · Jun 2026

Ilant Health provides end-to-end, clinician-led obesity and cardiometabolic care that combines behavioral therapy, medication (GLP-1 and non-GLP-1), and surgical options within a precision-medicine model that continuously adapts treatment to individual response. The company works directly with employers and health plans to deliver measurable clinical and financial outcomes and to manage both treatment costs and total cost of care. Early results reported by Ilant show members achieve an average 15% weight loss and an average of two additional mentally healthy days per month. Ilant emphasizes data- and analytics-driven care pathways, clinician oversight, and transparent contracting for medications; it has announced direct contracting and transparent pricing through Lilly’s Employer Connect program and is working with Novo Nordisk. The company presents itself as an AI-enabled healthcare services provider that aims to move obesity care from disconnected interventions to a continuous, outcomes-focused service. Ilant has raised over $22 million to date following the $15 million Series A and is partnering with employers and payers to scale its model.

Participated · Seed · Mar 2026

Sous offers an AI-driven growth platform that enables independent F&B creators to improve online visibility, convert digital traffic into direct sales, and automate customer engagement via continuous AI agents. The platform integrates with existing restaurant technology stacks and combines digital marketing and operational tools for restaurants. Sous was co-founded by Devon Scoulelis, Thomas Scholte and William Hurst (CTO). The company raised a €4M seed round led by Seed + Speed Ventures with participation from PeakBridge, āltitude, Gekko Capital and angel investors. Funds will be used to scale product and engineering teams, advance the platform’s AI automation capabilities, and support international expansion across Europe beginning in Germany. No revenue, user metrics or valuation were disclosed in the article.

Participated · Seed · Mar 2026

SOUS develops an AI-powered growth platform for independent restaurants and food & beverage businesses, building continuous AI agents that run in the background to improve discoverability, convert online traffic into direct sales, and automate marketing, brand presence, and customer communication. The platform positions itself as an end-to-end growth engine covering customer discovery through transaction and retention, and it integrates with existing restaurant tools such as Zenchef. SOUS aims to unlock additional revenue streams for operators, including takeaway, retail products, experiences, and subscriptions. The company was founded by Devon Scoulelis and Thomas Scholte, with William Hurst as co-founder and CTO, and is based in Amsterdam. With the recent €4M seed raise, SOUS plans to expand its product and engineering teams, further develop its AI capabilities, and begin international expansion in Europe starting with Germany.

Led · Equity · Nov 2025

KAAPA Biotech, headquartered in Karjalohja, Finland, develops high-purity functional mushroom extracts intended for use in wellness, nutrition, and supplement products. The company operates a fully vertically integrated model through its KAAPA Forest, KAAPA Mushrooms, and Nordic Mushrooms divisions, controlling everything from sustainable cultivation to proprietary extraction. Its network is reported to be the world’s largest chaga cultivation operation and has been expanded with new facilities in Paimio and Salo to boost capacity and research capabilities. KAAPA targets species such as lion’s mane, chaga, cordyceps, and reishi, quantifying their unique bioactive compounds to standardise potency and efficacy. Proprietary extraction processes deliver consistent concentrations of hericenones, betulinic acid, triterpenoids, and other actives that support cognitive health, immunity, and longevity. The firm is running clinical studies, including on chaga’s antioxidant and healthy-ageing potential, to underpin its health claims with reproducible data. With the fresh capital, KAAPA plans to expand production, deepen vertical integration, and advance its clinical research pipeline.